Cellavision is a Swedish-based medico company, founded in 2001 by Christer Fåhraues with the vision to digitalise traditional microscopy in the field of hematology. Today, more than four billion blood samples are taken each year of which around 15% require further analysis. Cellavision develops analyzers, software and applications that make it easier, faster and more efficient to carry out this “further analysis”, i.e. pre-classification of white-blood cell types or morphological characteristics of red-blood cells. Traditionally, this analysis has been carried out by laboratory personal using manual microscopy.
Today, Cellavision is the only serious provider of a commercial viable solution in the hematology market, with an estimated market penetration rate of around 18%. In 2017, Cellavision’s revenue amounted to SEK 309 million with an EBITDA margin of 32%.
William Demant Invest started investing in Cellavision in 2017, and has continually bought up Cellavision shares. With an ownership of just over 10%, William Demant Invest is the majority shareholder in the company.